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An established body of literature supports the hypothesis that activation of a local tissue angiotensin (ANG) system in the
extravascular tissue compartment of the lungs is required for lung ﬁbrogenesis. Transcriptional activation of the angiotensinogen
(AGT) gene is believed to be a critical and necessary step in this activation. This paper summarizes the data in support of this
theory and discusses transcriptional regulation of AGT, with an emphasis on lung AGT synthesis as a determinant of ﬁbrosis
severity. Genetic data linking AGT polymorphisms to the severity of disease in Idiopathic Pulmonary Fibrosis are also discussed.
1.Introduction
Pulmonary ﬁbrosis results from injury to the lung and an
ensuing ﬁbrotic response that leads to thickening of the
alveolar walls and the obliteration of alveolar air spaces.
If the etiology is unknown, the condition is designated
as idiopathic pulmonary ﬁbrosis (IPF) [1]. There are also
severalgroupsofxenobioticsorenvironmentaltoxinsknown
to cause pulmonary ﬁbrosis, for example, the antineo-
plastic agent bleomycin, the class III antiarrhythmic agent
amiodarone, gamma-irradiation, silicon dust, and asbestos
[2]. The main histological features of the ﬁbrotic lung are
persistent and unrepaired epithelial damage, proliferation
and accumulation of ﬁbroblasts and myoﬁbroblasts, and
increased collagen deposition [3]. This section will discuss
evidence that lung-derived angiotensinogen (AGT) plays an
important role in lung ﬁbrogenesis.
2. Lung-DerivedAGTinLungFibrogenesis
Numerous studies support the existence of “local” angi-
otensin (ANG) systems in various organs and tissues. For
example, the ANG II concentrations in the interstitial
compartment of heart and eye were found to be 5–100 fold
higher (about 50–500pM) than that in plasma (∼5–10pM)
[4, 5]. The higher interstitial levels of ANG II compared
to the circulating level could not be explained by diﬀusion
and/or receptor-mediated uptake of circulating angiotensin
II. These results thereby suggest that tissue angiotensin II is
largely, if not completely, synthesized locally. Furthermore,
cultured cells from various organs including heart [6],
vascular endothelium [7], brain [8–10], and lung [11]w e r e
shown to express the ANG system components such as AGT,
ANG II, and their corresponding converting enzymes and
angiotensin receptors. In contrast to the classical endocrine
“renin-angiotensin-aldosterone system” (RAAS) in which
the octapeptide angiotensin II is enzymatically cleaved from
AGT by the actions of renin and angiotensin-converting
enzyme (ACE), local angiotensin systems are categorized
as either “intrinsic” (independent of the endocrine RAAS)
or “extrinsic” (relying on the endocrine RAAS for some
of its components). An important distinction between the
endocrine and local tissue ANG systems is the fact that many
local ANG systems have been shown to be independent of
renin and ACE, but rather depend on other enzymes such
as cathepsin D, tonin, cathepsin G, or chymase, for the
enzymatic conversion of AGT to ANGII. This concept as it
applies to the lung will be discussed further below; in light
of the discussion to follow, in this paper the local pulmonary
system described here will be referred to as an “ANG system”
rather than an “RAAS” because it is not dependent on either
renin or aldosterone, at least as far as our current knowledge2 International Journal of Peptides
haselucidated. First, however, the evidence that lung-derived
angiotensinogen is involved in pulmonary ﬁbrosis will be
described.
It has been shown that two cell types in the lung produce
AGT: injured alveolar epithelial cells (AECs) and myoﬁ-
broblasts. Primary cultures of AECs exposed to apoptosis
inducers synthesize and secrete AGT and the processed
peptide ANG II in response to Fas ligand [12], TNF-alpha
[13], or bleomycin [14]. Primary cultures of myoﬁbroblasts
isolated from ﬁbrotic human lungs (IPF biopsies) also
expressed AGT mRNA and expressed and secreted the AGT
protein as well as the processed peptide ANGII [15], strongly
suggesting that human lung myoﬁbroblasts synthesize AGT
intheintactlung.Studiesofmyoﬁbroblastsisolatedfromthe
heart showed that these abnormal cells express the aspartyl
proteasecathepsinD[16],which,likerenin,alsocleavesAGT
to ANGI albeit at a lower pH optimum; this topic will be
discussed further below.
In addition to these cell culture studies, there is in vivo
evidence demonstrating the existence of lung-derived AGT.
EndogenousAGTmRNAwithinlungtissue(perfusedimme-
diately before harvesting to remove blood) was upregulated
in vivo as early as 3 hours after bleomycin instillation into rat
lungs;thiswasdemonstratedbyRTPCR,insituhybridization
and immunohistochemistry. In the rat model, AGT mRNA
and angiotensin peptides were localized in alveolar wall
cells within the alveolar corners, the location of type II
pneumocytes. These markers also colocalized with alpha-
smooth muscle actin (α-SMA), the standard marker of lung
myoﬁbroblasts [17]. Those data were the ﬁrst to suggest that
bleomycin activated the production of the local angiotensin
systems in vivo. Moreover, they were consistent with the
previous ﬁnding of epithelial cell death in the vicinity of
alpha-SMA-positive myoﬁbroblasts in ﬁbrotic human lung
[18]. In light of the earlier demonstration that ANGII is
an inducer of apoptosis in AECs [19], this ﬁnding thus
supports the theory that alveolar epithelial death adjacent to
myoﬁbroblastsiscaused,atleastinpart,bytheANGpeptides
theyrelease[15].Furthermore,inbiopsyspecimensobtained
from the lungs of patients with Idiopathic Pulmonary
Fibrosis (IPF), AGT mRNA and protein were 21-fold and
3.6-fold more abundant, respectively, in IPF biopsies relative
to biopsies of normal human lung [20]. The data from the
IPF lung biopsies are consistent with data from bleomycin-
induced rat lung ﬁbrosis models [17].
3. AGTTranscriptioninthe Lungas
the Rate-LimitingStep of Pulmonary
Angiotensin II Generation in
Bleomycin-Induced Pulmonary Fibrosis
Recently our research group demonstrated that intratracheal
administration of antisense oligonucleotides against AGT
mRNA prevented bleomycin-induced lung cell apoptosis
and lung ﬁbrogenesis by blockade of the synthesis of lung-
derived AGT [17]. Two important aspects of that study
were the ﬁndings that ﬂuorescently tagged antisense, when
administered intratracheally, were taken up exclusively by
the lungs, but less than 5% was taken up by liver or kidney.
Consistent with that ﬁnding, the antisense oligos completely
blocked the bleomycin-induced increase in lung tissue AGT,
buthadnoeﬀectonserum-borneAGTorcirculatingANGII.
Those data strongly implicated organ-speciﬁc transcription
of lung-derived AGT as a critical determinant of lung
ﬁbrogenesis.
Investigations of primary cultures of AECs and lung
explant cultures demonstrated some of the many factors
capable of inducing AGT expression in lung tissue. AGT
mRNA expression in primary AECs and the human AEC
cell line A549 is upregulated by, and functional AGT mRNA
is required for, the apoptotic response to Fas L, TNF-
α, bleomycin, and amiodarone; this was shown by the
demonstration that the apoptosis of primary AECs and A549
cells caused by these agents was blocked by the same AGT
antisense oligos used in the preceding paragraph, but not
by scrambled-sequence control oligonucleotides of the same
base composition as the antisense [21]. In another model of
cultured lung explants, in which the “endocrine” RAAS is
notactive,bleomycin-inducedcollagenaccumulationexvivo
also required AGT gene expression; the AGT antisense oligos
also blocked collagen deposition in this model [17].
Other considerations support the notion that local tran-
scription of AGT, as well as converting enzymes synthesized
locally rather than derived from the “endocrine” RAAS,
comprises an “intrinsic” ANG system that is upregulated in
lung injury but independent of the endocrine RAAS. In the
whole animal model, circulating levels of angiotensinogen
are known to be approximately equal to the Michaelis
Constant (Km)o fr e n i nf o ri t ss u b s t r a t e( a b o u t1 u M )
[22]. Therefore, the rate of angiotensin II synthesis can be
regulated by changes in angiotensinogen levels. Since the
normal concentration of AGT is near the Km for its cleavage
by renin [22], one might expect any change in AGT levels
to be accompanied by parallel changes in the formation
and actions of ANG II. Published ﬁndings support this
concept; for instance, transgenic mice overexpressing the rat
AGT gene are hypertensive [23] and mice underexpressing
the AGT gene are hypotensive [24]. In addition, for any
given level of renin activity, angiotensin II synthesis can be
altered by changes in the concentration of available AGT
[25]. For example, upregulation of AGT in tissue can alter
tissueconcentrationsofangiotensinII,particularly,intissues
which are not subjected to systemic short-loop or long-loop
feedback control [25]. In the bleomycin-induced pulmonary
ﬁbrosis model, AGT expression is rapidly upregulated in
blood-free lung tissue. This elevation of local AGT increased
thelungtissueANGIIconcentration.Furthermore,intratra-
chealdeliveryofantisenseoligosagainstAGTmRNAblocked
apoptosis of alveolar epithelial cells and subsequent collagen
deposition, both of which are consistent with the result that
the antisense oligos decreased local ANG II generation [17].
Whether the circulating ANGII contributes to the
local pulmonary ANGII that mediates lung ﬁbrogenesis
is unlikely, for several reasons. First, the concentration of
ANGII in the serum is extremely low, on the order of 1–
5pM, due to the many peptidases in the serum that rapidly
degradetheoctapeptide[26].MeasurementsoftissueANGIIInternational Journal of Peptides 3
by Marshall et al. [27] suggest that lung tissue ANGII
concentration is much higher, especially after lung injury
that activates the local lung ANG system. Moreover, uptake
from the circulation can be quantiﬁed by measuring steady-
state tissue and plasma levels of 125I-labelled ANG I and II
during 125I-ANGI and II infusion. Results obtained from
pigs [4, 28] showed that I25I-ANG II, but not 125I-ANG I,
accumulated in tissues like heart, kidney, and adrenal gland.
The absence of signiﬁcant tissue 125 I-ANG I accumulation
indicated that the presence of tissue ANG I, at least in those
organs, cannot be attributed to uptake from circulation.
Accumulation of 125 I-ANG II at tissue sites was largely
prevented by pretreatment with an AT1 receptor antagonist
[29], suggesting that uptake of ANG II is mediated via AT
1 receptor-dependent endocytosis. It is unlikely that AT2
receptors play a role in this process since AT2 receptors
do not internalize ANG II [30]. Similar conclusions about
that AT1 receptor mediates internalization of ANG II were
drawn from ANG II infusion studies in rats [31, 32].
However, comparison of the 125 I-labelled and endogenous
angiotensinlevelsrevealedthat,despitethesigniﬁcantuptake
of 125I-ANG II in various tissues, the majority (>90%)
of tissue ANG II is not derived from circulation. Instead,
it is synthesized from locally generated ANG I [33]. In
the lung ANGII uptake may not exist as treatment with
losartan increased rather than decreased pulmonary ANG II
concentration [27].
Moreover, several lines of evidence argue that enzymes
other than renin and ACE are involved in local ANGII gener-
ation from lung-derived AGT, in contrast to the “endocrine
RAAS” which is dependent on these two enzymes. First, the
ANGII-dependent apoptosis of alveolar epithelial cells that
results from exposure to bleomycin was shown to require
cathepsin D, an aspartyl protease that serves the same func-
tion as renin, although at a lower (∼6.0) pH optimum [34].
The induction of apoptosis both activated and upregulated
cathepsin D and AGT within the target cell itself and also
promotedtheirreleaseintotheextracellularspace[ibid].The
latter may be particularly important in light of the relatively
lowpHwithintheaqueousextracellularenvironmentimme-
diately above the type II alveolar epithelial cell in vivo. This
region, known as the “alveolar hypophase” or subphase, is an
aqueouslayerimmediately abovetheepithelialcellbutbelow
the surfactant phospholipid monolayer. Experiments with
microelectrodes have shown this microenvironment to have
a pH of about 6.6–6.9, due to proton pumps and Na+/K+-
ATPases on the AEC which function in unidirectional
energy-dependent water movement out of the alveoli [35].
Thus, AEC-derived AGT and cathepsin D are released from
AECs after lung injury into a microenvironment with a pH
favorable for cathepsin D-mediated cleavage of AGT to ANG
I. Indeed, even if renin were sequestered from the serum,
the low pH in this microenvironment would be predicted
to favor cathepsin D activity over that of renin. In addition,
cathepsin D was shown to be upregulated in ﬁbrotic human
lung[36]andinratlungepithelialcellsundergoingapoptosis
in vitro in response to advanced glycation end products [37].
Likewise,inhibitorsofchymase,oneoftheotherenzymes
known to have the same ability as ACE to convert ANGI to
ANGII, have been shown to inhibit paraquat-induced lung
injury and ﬁbrosis in mice [38] and bleomycin-induced lung
ﬁbrosis in hamsters [39]. Thus, the presence of renin or ACE
in the local pulmonary ANG system is not necessary for
conversion of AGT to ANGII. Taken together, our results and
those of other groups strongly suggest that the local ANG
system described here does not require enzymes from the
endocrine RAAS and that expression of AGT de novo in the
lung is the most likely rate-limiting step for angiotensin II
generationwithintheextravascularcompartmentofthelung
parenchyma.
4. Regulation of Angiotensinogen
GeneExpression
4.1. The Angiotensinogen Gene. The human angiotensinogen
gene is located on chromosome 1q42-q43 and contains
5exons/4 introns showing organization similar to other
serine protease inhibitors (serpins) superfamily to which
AGT belongs. The human AGT gene encodes the human
angiotensinogen molecule, an β2-globulin protein (485
amino acid), with a molecular weight of about 61kDa.
Exon 1 of the human AGT gene encodes for a short 37bp
5  untranslated tract, with the second exon encoding the
initiation methionine, signal peptide, and the majority of
the mature protein [40, 41]. AGT abundance is regulated
at the transcriptional level through hormonal and cell-type-
speciﬁc regulators.
4.2. Constitutive AGT Gene Expression. Constitutive human
AGT gene transcriptional control has been studied exten-
sively in liver [40]. The human angiotensinogen core pro-
moter element 1 (AGCE1) site, located between the TATA
box and transcription initiation site, was shown to be a
critical regulator of AGT transcription by binding to human
angiotensinogen core promoter binding factor 1(AGCF1) in
the human hepatoma cell line HepG2 cells [42]. USF1 has
been identiﬁed as a component of AGCF1 [43]. AGCE1 was
also shown to be required for the activity of an upstream
AGT enhancer, ATF-like element (ALE) [44]. In addition to
AGCE1, Yanai et al. also describes two AGCE2 sites, located
upstream and downstream of the transcription initiation
site that show a possible cell-type-dependent function [45].
The hepatocyte nuclear factor 4 (HNF4) was also shown to
potentiate human AGT (hAGT) promoter activity in HepG2
cells [46].
Other cell type-dependent elements controlling AGT
transcription are direct repeat sequences (DR) in AGT pro-
moter that contribute 50 or >95% to AGT transcription in
liver or kidneys, respectively, whereas the same sequences
are not required in the heart and brain [47], and a 3 -
downstream enhancer that binds an AP-3-related factor and
human angiotensinogen enhancer factor-1 (hAEF-1) [48].
In kidney cells, intrarenal AGT expressed in renal proximal
tubular cells was shown to be regulated by nuclear factor-
κB( N F - κB) binding to an NF-κB-binding site in the hAGT
promoter region [49].4 International Journal of Peptides
4.3. Regulated AGT Gene Expression in Diﬀerent Tissues.
Inducible human AGT transcription has been studied in
response to several factors. In HepG2 cells, interleukin-
(IL-) 6 induces AGT transcription via STAT3 binding to
one of three acute-phase response elements (APREs) present
between −350 and −122 upstream of transcription start site
[50]. Recently, Jain et al. suggested that three transcription
factors, glucocorticoid receptor (GR), STAT-3, and HNF-1α,
bind to the APREs region of the hAGT gene promoter and
are responsible for IL-6-induced promoter activity of this
gene in liver cells [51]. Upregulation of human AGT gene
transcription in Hep3B hepatocytes by interferon-gamma
was shown to involve STAT1-binding motif in the AGT
promoter between −271 and −279 in a mechanism separate
from IL-6 upregulation of AGT by STAT3 [52].
Other inducers of AGT transcription include estrogen,
through an estrogen responsive element near TATA box of
the promoter [53]. In a study suggesting relation between
adipose AGT secretion in obesity and elevated blood pres-
sure, AGT gene expression and secretion in adipose tissue
were found to be stimulated by cyclic AMP via increased
DNA cyclic AMP-responsive element- (CRE-) binding activ-
ity [54].
Repression of AGT gene transcription was described by
Date et al. [55], where Finb, a multiple zinc ﬁnger protein,
was reported to repress transcription of the AGT gene via
binding of two elements in the 5  ﬂanking region of the
human AGT promoter [56]. Expression of AGT gene was
also shown to be repressed in HepG2 cells in response to bile
acids via the small heterodimer partner (SHP) acting on the
binding site of hepatocyte nuclear factor-4 (HNF-4) on the
AGT gene promoter [56].
4.4. Regulated AGT Gene Expression in Pulmonary Fibrosis.
As angiotensinogen is the precursor protein for the ANGII
peptide, the regulation of AGT gene expression in the lung
under ﬁbrotic conditions has been studied by our research
group in response to proﬁbrotic and proapoptotic inducers.
In cultured pulmonary epithelial cells, the antiarrhythmic
drug amiodarone, which is ﬁbrogenic for the lungs at
therapeutic doses, induced AGT transcription through the
AP-1 site present between the TATA box and transcription
start site [57]. Transforming growth factor-beta1 (TGF-β1),
the prototype mediator of extracellular matrix deposition in
the lungs and other tissues [1], was found to upregulate AGT
transcription in human lung ﬁbroblasts [57]. Mechanisms
for this regulation required binding of both the AP-1 family
transcription factor JunD and hypoxia inducible factor-
1 alpha (HIF-1α) to the AGT core promoter [58]; the
signiﬁcance of these factors, especially HIF-1α, is discussed
further in the following paragraphs.
4.5. Hypoxia, Angiotensin, and Pulmonary Fibrosis. It is no-
table that hypoxia inducible factors have been previously
suggested to be involved in the pathogenesis of lung ﬁbrosis.
In alveolar epithelial cells, hypoxia was found to induce
apoptosis of primary cultures of alveolar epithelial type II
cells in a manner comparable to the eﬀects of ANGII on
these cells [59]. HIF-1α overexpression was detected in the
so-called “hyperplastic epithelium” of ﬁbrotic lungs [60],
which is found in the same regions immediately adjacent
to the myoﬁbroblast foci in which the apoptotic epithelia
described above were found [18]. Moreover, the activation
ofHIFpathwaysresultsinepithelial-mesenchymaltransition
and ﬁbrosis [61, 62]. On the other hand, in lung ﬁbroblasts
the overexpression of von Hippel-Lindau protein (pVHL)
that targets HIF for degradation failed to decrease HIF
signaling [63], and the TGF-β1 that mediates transition of
ﬁbroblaststomyoﬁbroblastsincreasesthenuclearabundance
of HIF-1α protein [58]. In light of our demonstration that
the transcription of AGT in response to TGF-β1 is mediated
by the hypoxia-signaling transcription factor HIF-1α, these
ﬁndings suggest a molecular mechanism linking hypoxia-
signaling and ﬁbrogenic stimuli in the lungs by modulation
of the levels of the ANGII peptide precursor AGT [58, 59].
5. SNPs inAGTImportantinOrgan Fibrosis
As discussed above, the severity of ﬁbrotic diseases in the
heart and kidney is inﬂuenced by ANGII. In the heart,
ANGII plays a role in the hypertrophy of cardiomyocytes,
ﬁbroblast hyperplasia, and interstitial cardiac ﬁbrosis [64].
Similar eﬀects are also seen in the liver. The progression of
congenital hepatic ﬁbrosis is mediated through the increase
of angiotensin-converting enzyme (ACE), ANGII, and TGF-
β1[ 65]. This was also reﬂected in the disease progression of
liver injury following chronic hepatitis C infection, in which
liver ﬁbrosis severity was highly associated with genotypes
leading to higher expression of TGF-β1a n dA G T[ 66]. As
discussed above, local expression of AGT is a requirement
for the experimental induction of lung ﬁbrogenesis [1, 16];
additionally, ANGII is a mediator of the ﬁbroproliferative
response in acute lung injury [27]
Activated epithelial cells and myoﬁbroblasts are sources
of ANGII. The proﬁbrotic eﬀect of ANGII is mediated
through the stimulation of TGF-β1 and the induction of
epithelial mesenchymal transition (EMT) resulting in the
diﬀerentiation of epithelial cells, in addition to normal
ﬁbroblasts,intomyoﬁbroblasts.Excessdepositionofcollagen
by myoﬁbroblasts leads to the ﬁnal result of ﬁbrosis. Recent
work showed that AGT mRNA and protein are constitutively
expressed in human lung myoﬁbroblasts in response to
“autocrine loops” of TGF-β1 and AGT expression which
drive and expand each other unless interrupted [1]. Most
important for the following discussion is that the upregula-
tion of AGT by TGF-β1 is mediated through the AGT core
promoter, which contains three single nucleotide polymor-
phisms (SNPs), A-20C, C-18T, and G-6A [43, 58, 67].
In ﬁbrosis of organs other than the lungs, interindividual
variability in the progression or severity of ﬁbrotic disease is
correlatedwithgeneticvariants inAGTatthosethreegenetic
loci. In a Spanish IPF cohort, it was demonstrated that the
AA genotype of G-6A SNP was signiﬁcantly associated with
disease progression as measured by changes in the alveolar-
arterial oxygen gradient over time [68]. This same genotype
was also linked to an increase in hepatic ﬁbrosis in people
with chronic hepatitis C infections and in advanced liver
ﬁbrosis in the severely obese [66, 69]. In the heart, G-6AInternational Journal of Peptides 5
and A-20C SNPs are associated with an increase in mean
carotid intimal-medial thickening (IMT) in females [70]. In
a similar manner, both of these SNPs displayed a signiﬁcant
relationship in liver cirrhosis in patients with chronic
hepatitis B [70]. The G-6A SNP is found in partial linkage
disequilibrium with A-20C and C-18T. As a consequence, a
higher frequency of G-6A is found with C alleles at the −20
and −18positions.DuetothescarcityoftheC-18Tgenotype
in the human population, G-6A is more frequently seen with
A-20C.
The progression of ﬁbrosis is exacerbated when variants
in AGT are inherited in conjunction with variants in other
genes. For example, the inheritance of variants in TGF-β1
andAGTtogetherisassociatedwithincreasedstagingofhep-
atic ﬁbrosis [66]. Individually, these variants are correlated
with higher stages of ﬁbrosis; however, the inheritance of
both the arginine/arginine genotype in codon 25 of TGF-
β1 and the AA genotype in −6 of AGT, together, led to
more progressive ﬁbrosis than either variant alone [ibid].
This eﬀect was also associated with advanced hepatic ﬁbrosis
in obese patients with nonalcoholic fatty liver disease [69].
The interaction of A-6C of AGT with the I allele of ACE leads
to an increase in the mean IMT in the population as a whole
[70].
Based on these studies, it is hypothesized by our research
group that the progression and/or severity of collagen
deposition in IPF may be predicted by a risk haplotype in the
AGT gene. The theorized risk haplotype that will be found
to predict IPF severity is CCA (−20, −18, and −6, resp.).
In addition, it is predicted that inheritance of this variant
with the arginine/arginine genotype in codon 25 of TGF-β1
and/or the D allele of ACE, which also has been associated
with more severe lung ﬁbrosis [71], will further intensify
the progression or severity of IPF. Investigations of these
hypotheses are currently underway.
6.ClinicalSigniﬁcance
Given the widespread use and relative safety of inhibitors of
the ANG system in cardiovascular diseases, the potential of
these inhibitors in the therapeutic management of patients
with lung ﬁbrosis is of high interest. Initial attempts to ﬁnd
therapeutic beneﬁt of ACE inhibitors through retrospective
analyses of clinical data from individuals receiving ACE
inhibitors for other comorbid conditions did not ﬁnd
therapeutic improvement of lung ﬁbrosis [72, 73]. However,
these studies were not designed as prospective tests of
lung ﬁbrosis alone nor were the subjects chosen randomly.
Moreover, the above discussion of ACE-independent path-
ways of ANGII formation in local tissue ANG systems
argues against the prospect of therapeutic beneﬁt through
inhibition of ACE. Indeed, a recent study of the counter
regulatory ACE-2/angiotensin 1-7/mas axis [74] has shown
that ACE inhibitors might, at least theoretically, prove to
be counterproductive through their potential reduction of
the inhibitory peptide angiotensin 1–7. This heptapeptide,
which is the product of ANGII degradation by ACE-2,
inhibits the actions of ANGII and is normally present
in much higher levels than the proﬁbrotic ANGII [ibid].
On the other hand, signiﬁcant published data support the
potential eﬃcacy of AT1 receptor antagonists in animal
models (see previous discussion), and several clinical trials
of AT1 receptor blockers in IPF are currently underway [75].
An alternate therapeutic strategy might be the reduction of
lung-speciﬁc AGT transcription through antisense oligonu-
cleotides delivered speciﬁcally to the lungs [17].
7. Summary and Conclusions
Activation of the local ANG system in lung tissue is now
known to be a required event in the pathogenesis of exper-
imental lung ﬁbrosis. Data from lung biopsies obtained
from patients with Idiopathic Pulmonary Fibrosis (IPF) are
consistent with the hypothesis that a local lung ANG system
also is activated in human lung ﬁbrosis. Transcription of
the angiotensinogen (AGT) gene is the rate-limiting step in
this activation, and antisense oligonucleotides against AGT
mRNA prevent both lung epithelial cell apoptosis and the
accumulation of lung collagens. Single nucleotide polymor-
phisms (SNPs) in the AGT gene, some of which are known
to be signiﬁcantly associated with essential hypertension and
higher rates of AGT gene transcription, have been shown to
associate with more rapid progression of IPF. It is hoped
that the further analysis of additional SNPs in the AGT
gene will reveal an “IPF risk haplotype” in AGT that might
hold signiﬁcant predictive value in the treatment of IPF and
possibly other lung diseases that are inﬂuenced by lung AGT
expression.
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